Exhibit 10.1

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Statement of Work

 

To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated
16 of October 2007

 

Supplemental analytical services

 

Number

 

RDS-001-SC003

 

 

Product Code/Name

 

RDS-001 Abaloparatide

 

 

Description of the proposed change

 

Supplemental services requested by Radius:

1)             Concentration testing with FG2 on 10 samples from Bioagilytix

2)             Reissue CoA of reference standard 8AK1R data with current TG2/FG2
and M-076 methods

 

 

 

Price Agreed

 

1.              [*]€

2.              [*]€

 

Total: [*]€

 

 

Radius

 

Name: Naveen Palwai

Signature: /s/ Naveen Palwai

 

Date: 02/03/2016

Radius

 

Name: Wajiha Khan

Signature: /s/ Wajiha Khan

 

Date: 02/03/2016

Lonza Sales AG

 

Name: Paul Tastenhoye

Signature: /s/ Paul Tastenhoye

 

Date: 29/01/2016

Lonza Sales AG

 

Name: Frederique Mutterer

Signature: /s/ Frederique Mutterer

 

Date: 29/01/2016

 

Additional notes: /

 

--------------------------------------------------------------------------------

[*] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

1

--------------------------------------------------------------------------------

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Detailed description of the proposed change

 

Activity 1: Concentration testing with FG2 on 10 samples from Bioagilytix +
issue of an official test report.

Activity 2: Reissue CoA of reference standard 8AK1R data with current TG2/FG2
and M-076 methods

 

Timescale

 

By February 5th 2016

 

Price and Terms of Payment

 

1. Price

 

·              Activity 1: [*]€

·               Activity 2: [*]€

·               Total price: [*]€

 

2.              Payment

 

100% upon completion

 

oooOOOooo

 

--------------------------------------------------------------------------------

[*] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

2

--------------------------------------------------------------------------------